Expansion of SB623's sales territories to Europe, Asia, South America and other regions
First written in FY2017. 4 of 6 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「Expansion into other regions, including Europe and Asia, beyond the United States and Japan, where the company has experience conducting clinical trials, is also an important management strategy, and the company will pursue this as development progresses.」
The policy of expanding into Europe, Asia and other regions beyond Japan and the United States in line with development progress has been reaffirmed. - FY2022-Q2RestatedAnnual report
「On 1 February 2021, the company established SanBio Asia Pte. Ltd., its first subsidiary in Asia, in Singapore, with the aim of expanding its sales channels in the region.」
The establishment of a Singapore subsidiary to expand sales channels in Asia has been reaffirmed as part of the existing regional expansion policy. - FY2021AdvancedAnnual report
「In February 2021, the company established a subsidiary in Singapore in preparation for a global supply chain for the group's regenerative cell therapy products, including SB623, expansion of sales territories in Asia and business development activities.」
The policy of expanding sales territories to Europe, Asia and other regions has resulted in the establishment of a Singapore subsidiary as a specific step toward expanding sales territories in Asia and pursuing business development. - FY2020RestatedAnnual report
「The company will seek to expand its sales territories, including by exploring partnerships with pharmaceutical companies covering Europe, Asia, South America and other regions so that SB623 can be sold in those markets in the future.」
The policy of using Japan and the United States as a base for expanding sales territories to Europe, Asia, South America and other regions, and exploring partnerships with pharmaceutical companies, has been reaffirmed. - FY2019RestatedAnnual report
「The company will seek to expand its sales territories, including by exploring partnerships with pharmaceutical companies covering Europe, Asia, South America and other regions so that SB623 can be sold in those markets in the future.」
The policy of expanding sales territories beyond North America and Japan to Europe, Asia, South America and other regions, and exploring partnerships with pharmaceutical companies, has been reaffirmed. - FY2017First statedAnnual report
「The company will seek to expand its sales territories, including by exploring partnerships with pharmaceutical companies covering Europe, Asia, South America and other regions so that SB623 can be sold in those markets in the future.」
The company plans to expand its sales territories beyond North America and Japan to Europe, Asia, South America and other regions, and to explore partnerships with pharmaceutical companies covering those regions.